Tests gene-edited immune cells for glioblastoma, a brain tumor
Tests donor immune cells, given locally, in adults with glioblastoma brain cancer.
Plain-language title generated from the registry record
Registry title: Allogeneic γδT Cells in Glioblastoma
Key facts
- Where
- Beijing and Zhengzhou, ChinaSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-70 with glioblastoma that has come back or keeps growing after full treatment. It tests locally delivered donor γδ T cells (ABOUT γδT cells).
- Age
- 18-70 years (both ends included)
- Sex
- Women and men
- Disease stage
- Glioblastoma (WHO grade IV) confirmed by biopsy or tissue exam, with imaging suggesting it keeps progressing or has come back after comprehensive treatment. At least one lesion that can be evaluated.
- Earlier treatment
- Radiotherapy or systemic therapies (including temozolomide/bevacizumab or other agents) must have been finished at least 4 weeks before joining. Side effects from earlier treatment must be grade 1 or milder (except alopecia or leukoplakia).
Main reasons for not taking part
- Active hepatitis B or C, HIV infection, or other untreated active infection
- Pregnant or breastfeeding women
- Organ failure
- Chronic disease needing immune or hormone therapy
- History of organ transplant, or waiting for one
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07144735, who can take part
Where in China
- Peking University Third HospitalBeijing, ChinaTaking people
- Henan Academy of Innovations in Medical ScienceZhengzhou, ChinaTaking people
- Zhengzhou Second HospitalZhengzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University Third Hospital
- Trial code
- NCT07144735
- Record updated
- 27 August 2025
- Original description
This first-in-human clinical study aims to evaluate the safety and feasibility of locally delivered, allogeneic γδ T cells (genetically edited with ARIH1 and BCL11b knockout, designated ABOUT γδT cells) in patients with glioblastoma multiforme (GBM). The engineered effector cells are delivered via localized administration to selectively target and eliminate residual GBM cells. ABOUT: ARIH1 and BCL11b knockOUT γδ T cells.Read full original descriptionShow less
Allogeneic Gamma Delta (γδ) T Cells for the Treatment of Glioblastoma
This first-in-human clinical study aims to evaluate the safety and feasibility of locally delivered, allogeneic γδ T cells (genetically edited with ARIH1 and BCL11b knockout, designated ABOUT γδT cells) in patients with glioblastoma multiforme (GBM). The engineered effector cells are delivered via localized administration to selectively target and eliminate residual GBM cells. ABOUT: ARIH1 and BCL11b knockOUT γδ T cells.
Inclusion: Male or female, age 18-70 years old (both ends included); At least one evaluable lesion with previous biopsy or pathohistologic confirmation of glioblastoma (WHO grade IV), with imaging suggestive of continued progression or recurrence after comprehensive treatment; Karnofsky Performance Status (KPS) ≥ 60%; Life expectancy > 4 weeks; Patients who completed radiotherapy or systemic therapies (including temozolomide/bevacizumab or other agents) for at least 4 weeks prior to enrollment. All prior treatment-related toxicities should be defined as ≤ grade 1 (except for toxicities such as alopecia or leukoplakia) according to the Common Terminology Standard for Adverse Events (CTCAE 6.0); Must be able to undergo an MRI with contrast; Must have adequate organ and marrow function as defined below:; White blood cell count (WBC) ≥ 3 x 10\^9/L; Absolute neutrophil count (ANC) > 1 x 10\^9/L; Hemoglobin (Hb) ≥ 90 g/L; Platelet (PLT) ≥ 80×10\^9/L; Albumin transaminase (ALT) \& albumin transaminase (AST) < 1.5 × institutional upper limit of normal (ULN); Serum creatinine (Cr) < 1.5 x institutional ULN; Total bilirubin < 1.5 x institutional ULN; PT \& PTT ≤ 1.25 x institutional ULN; No obvious hereditary diseases; Normal cardiac function with left ventricular ejection fraction >55%; No bleeding and coagulation disorders; Absence of positive blood cultures for bacteria, fungus, or virus within 48-hours prior to ABOUT γδT cell infusion and/or there aren't any indications of meningitis; Fertile women must have had a pregnancy test with a negative result within 7 days prior to the start of treatment, and subjects are willing to use contraception (hormonal or barrier method of birth control or abstinence) during the clinical trial and for 6 months after the last cell infusion; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately; Signed, written informed consent.
Exclusion: Active hepatitis B or C virus, HIV infection, or other untreated active infection; Participants with organ failure; Participants with a chronic disease requiring immunologic or hormonal therapy; Participants with an allergy to immunotherapy and related cells; Participants with uncontrolled intercurrent illness; Participants with psychiatric illness/social situations that would limit compliance with study requirements; Participants with a history of organ transplantation or who are awaiting organ transplantation; Pregnant and lactating women.